Evidence map›Paper›PMID 42458495›Full record

Trial reportRespiratory research2026

Biomarker profiles in idiopathic and progressive pulmonary fibrosis after LPA

Toby M Maher, Naftali Kaminski, Fang Wang, Manuela Funke-Chambour, Chun Wu, Yanhua Hu, Supriya Sharma, Peter Schafer, Matthew Schaller, Gerald Horan

Registry-linked trialAbstract readClinical Trial, Phase IIRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04308681 (A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04308681 phase2completednot on this map

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis

TypeinterventionalSponsorBristol-Myers SquibbRan2020 to 2023Enrolled403ConditionsPulmonary FibrosisArmsBMS-986278 Placebo, BMS-986278
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Toby M MaherDepartment of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, 1510 San Pablo St. HC1, Suite 513, Los Angeles, CA, 90033, USA. tobymahe@usc.edu.
Naftali KaminskiPulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, USA.
Fang WangBristol Myers Squibb, Princeton, NJ, USA.
Manuela Funke-ChambourDivision of Pulmonology, Department of Medicine, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Chun WuBristol Myers Squibb, Princeton, NJ, USA.
Yanhua Hu *Bristol Myers Squibb, Princeton, NJ, USA.
Supriya Sharma *Bristol Myers Squibb, Princeton, NJ, USA.
Peter Schafer *Bristol Myers Squibb, Princeton, NJ, USA.
Matthew SchallerBristol Myers Squibb, Princeton, NJ, USA.
Gerald Horan *Bristol Myers Squibb, Princeton, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn a phase 2 trial (NCT04308681), treatment with admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 (LPA

methodsPatients with IPF or PPF were randomized 1:1:1 to receive twice-daily admilparant (30 or 60 mg) or placebo for 26 weeks; background antifibrotics were allowed. The IPF and PPF cohorts were analyzed separately. Changes from baseline (CfB) in serum proteins associated with epithelial injury, inflammation, and fibrosis were measured by quantitative immunoassays at 4, 12, and 26 weeks, and compared between patients who received admilparant versus placebo. Pharmacodynamic biomarker changes were evaluated by clinical response status at week 26. Plasma samples from patients with IPF were assessed post hoc by SomaScan v4.1 proteomics assay. Statistical evaluations used linear mixed-effects models.

resultsIn the IPF cohort (n=276), nine serum proteins showed significant CfB (p<0.05) at week 26 in patients treated with 60-mg admilparant versus placebo, including increased adiponectin, MMIF, CD163, CEA, and ENRAGE, and decreased markers of epithelial injury and fibrosis (CA-125/MUC16, MMP-7, TN-C, PRO-FIB). In the PPF cohort (n=116), significant differences at week 26 (p<0.05) were observed for 11 serum proteins, including increased CEA and decreased periostin, IL6Rβ, CD163, KIM-1, multiple inflammatory markers (YKL-40, VCAM-1, PECAM-1, ferritin), and collagen degradation markers (C3M and C4M). Two serum proteins, CA-125 and TN-C, showed significantly greater CfB (p<0.05) in responders compared with non-responders in the IPF cohort. Plasma proteomic analysis identified differential expression (adjusted p<0.1) of adiponectin, CKMT1A, ANGPTL3, PDCD1LG2, and IGFBP6 at week 26 in patients with IPF treated with 60-mg admilparant versus placebo.

conclusionsTreatment with 60-mg admilparant improved circulating biomarkers associated with epithelial injury and fibrosis in IPF, and with inflammation, fibrosis, and collagen degradation in PPF. Proteomic analysis identified additional biomarkers associated with mitochondrial and metabolic pathways in IPF. These findings expand our understanding of potential mechanisms of LPA

Indexed as

Disease ProgressionIdiopathic Pulmonary FibrosisPulmonary FibrosisReceptors, Lysophosphatidic AcidAgedBiomarkersDouble-Blind MethodFemaleHumansMaleMiddle AgedTreatment OutcomeBiomarkersReceptors, Lysophosphatidic AcidAdmilparantBiomarkersIdiopathic pulmonary fibrosisLysophosphatidic acid receptor 1 antagonistProgressive pulmonary fibrosisRandomized clinical trial

Identifiers

PMID42458495
PMCPMC13670599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.